Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic

Journal of Medicinal Chemistry

Volumn 51, Issue 16, 2008, Pages 5109-5117

  Balboni, Gianfranco ^a,b   Fiorini, Stella ^b   Baldisserotto, Anna ^b   Trapella, Claudio ^b   Sasaki, Yusuke ^c   Ambo, Akihiro ^c   Marczak, Ewa D ^d   Lazarus, Lawrence H ^d   Salvadori, Severo ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLYCINE; HYDROGEN; LEAD; NALTRINDOLE; NITROGEN; OPIATE DERIVATIVE;

AGITATION; ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIRALITY; CONTROLLED STUDY; CONVULSION; DRUG ACTIVITY; MALE; METHYLATION; MOUSE; NONHUMAN; PHARMACOPHORE; SEDATION; TAIL FLICK TEST;

ANALGESICS; ANIMALS; DIPEPTIDES; MICE; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TAIL; TETRAHYDROISOQUINOLINES;

EID: 50249141166     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800587e     Document Type: Article

References (49)

1. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ Opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
2. Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini, R.; Tomatis, R.; Lazarus, L. H.; Tancredi, T. Selective opioid dipeptides. Biochem. Biophys. Res. Commun. 1994, 198, 933-939.
3. Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, B. J.; Lemieux, C.; Chung, N. N. Differential stereochemical requirements of μ vs δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11871-11875.
4. Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
5. Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent δ-opioid receptor antagonist into a potent δ agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
6. Balboni, G.; Onnis, V.; Congiu, C.; Zotti, M.; Sasaki, Y.; Ambo, A.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H.; Trapella, C.; Salvadori, S. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J. Med. Chem. 2006, 49, 5610-5617.
7. Tryoen-Toth, P.; Décaillot, F. M.; Filliol, D.; Befort, K.; Lazarus, L. H.; Schiller, P. W.; Schmidhammer, H.; Kieffer, B. L. Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors. J. Pharmacol. Exp. Ther. 2005, 313, 410-421.
8. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. Potent δ-opioid receptor agonists containing the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5556-5563.
9. Aguila, B.; Coulbault, M.; Léveillé, F.; Davis, A.; Tóth, G.; Borsodi, A.; Balboni, G.; Salvadori, S.; Jauzac, P.; Allouche, S. In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance. Br. J. Pharmacol. 2007, 152, 1312-1324.
10. 2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 2008, 29, 93-103.
11. 18F-labeled δ-opioid receptor antagonist derived from the Dmt-Tic pharmacophore for positron emission tomograpgy imaging. J. Med. Chem. 2008, 51, 1817-1823.
12. Snook, L. A.; Milligan, G.; Kieffer, B. L.; Massotte, D. μ-δ opioid receptor functional interaction: insight using receptor-G protein fusions. J. Pharmacol. Exp. Ther. 2006, 318, 683-690.
13. Snook, L. A.; Milligan, G.; Kieffer, B. L.; Massotte, D. Co-expression of mu and delta opioid receptors as receptor-G protein fusion enhances both mu and delta signalling via distinct mechanisms. J. Neurochem. 2008, 105, 865-873.
14. Salvadori, S.; Trapella, C.; Fiorini, S.; Negri, L.; Lattanzi, R.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H.; Balboni, G. A new opioid designed multiple ligand derived from the μopioid agonist endomorphin-2 and the δ opioid antagonist pharmacophore Dmt-Tic. Bioorg. Med. Chem. 2007, 15, 6876-6881.
15. Lee, Y. S.; Petrov, R.; Park, C. K.; Ma, S. W.; Davis, P.; Lai, J.; Porreca, F.; Vardanyan, R.; Hruby, V. J. Development of novel enkephalin analogues that have enhanced opioid activities at both μ and δ opioid receptors. J. Med. Chem. 2007, 50, 5528-5532.
16. Dai, X.; Cui, S. G.; Li, S. R.; Chen, Q.; Wang, R. Melatonin attenuates the development of antinociceptive tolerance to delta-, but not to mu-opioid receptor agonist in mice. Behav. Brain Res. 2007, 182, 21-27.
17. Jutkiewicz, E. M. The antidepressant-like effects of delta-opioid receptor agonists. Mol. Interv. 2006, 6, 162-169.
18. Narita, M.; Kuzumaki, N.; Miyatake, M.; Sato, F.; Wachi, H.; Seyama, Y.; Suzuki, T. R. Role of δ-opioid receptor function in neurogenesis and neuroprotection. J. Neurochem. 2006, 97, 1494-1505.
19. Hill, M. P.; Hille, C. J.; Brotchie, J. M. Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease. Drug News Perspect. 2000, 13, 261-268.
20. Tegeder, I.; Geisslinger, G. Opioids as modulators of cell death and survival-unravelling mechanism and revealing new indications. Pharmacol. Rev. 2004, 23, 351-366.
21. Watson, M. J.; Holt, J. D.; O'Neill, S. J.; Wei, K.; Pendergast, W.; Gross, G. J.; Gengo, P. J.; Chang, K. J. ARD-353 [4-((2R,5S)-4- (R)-(4-diethylcarbamoxylphenyl)(3-hydroxyphenyl)methyl-2, 5dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide δ receptor agonist, reduces myocardial infarct size without central effects. J. Pharmacol. Exp. Ther. 2006, 316, 423-430.
22. Pol, O.; Palacio, J. R.; Puig, M. M. The expression of δ-and κ-opioid receptors is enhanced during intestinal inflammation in mice. J. Pharmacol. Exp. Ther. 2003, 306, 455-462.
23. Stein, C.; Schäfer, M.; Machelska, H. Attaching pain at its source: new perspectives on opioids. Nat. Med. 2003, 9, 1003-1008.
24. 1- benzimidazole alkylation. J. Med. Chem. 2005, 48, 8112-8114.
25. 2-Bid (UFP-502). Bioorg. Med. Chem. 2008, 16, 3032-3038.
26. Torregrossa, M. M.; Jutkiewicz, E. M.; Mosberg, H. I.; Balboni, G.; Watson, S. J.; Woods, J. H. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res. 2006, 1069, 172-181.
27. 2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies. Peptides 2006, 27, 3322-3330.
28. Nestor, J. J., Jr.; Horner, B. L.; Ho, T. L.; Jones, G. H.; McRae, G.; Vickery, B. H. Synthesis of a novel class of heteroaromatic amino acids and their use in the preparation of analogues of luteinizing hormone-releasing hormone. J. Med. Chem. 1984, 27, 320-325.
29. Lee, Y. S.; Nyberg, J.; Moye, S.; Agnes, R. S.; Davis, P.; Ma, S. W.; Lai, J.; Porreca, F.; Vardanyan, R.; Hruby, V. J. Understanding the structural requirements of 4-anilinopiperidine analogues for biological activities at μ and δ opioid receptors. Bioorg. Med. Chem. Lett. 2007, 17, 2161-2165.
30. Codd, E. E.; Carson, J. R.; Colburn, R. W.; Dax, S. L.; Desai-Krieger, D.; Martinez, R. P.; McKown, L. A.; Neilson, L. A.; Pitis, P. M.; Stahle, P. L.; Stone, D. I.; Streeter, A. J.; Wu, W. N.; Zhang, S. P. The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent mu opioid RWJ-413216. J. Pharmacol. Exp. Ther. 2006, 318, 1273-1279.
31. Jutkiewicz, E. M.; Baladi, M. G.; Folk, J. E.; Rice, K. C.; Woods, J. H. The convulsive and electroencephalographic changes produced by nonpeptidic delta opioid agonists in rats: comparison with pentylenetetrazol. J. Pharmacol. Exp. Ther. 2006, 317, 1337-1348.
32. Danielsson, I.; Gasior, M.; Stevenson, G. W.; Folk, J. E.; Rice, K. C.; Negus, S. S. Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacol, Biochem. Behav. 2006, 85, 428-434.
33. Wentland, M. P.; Sun, X.; Cohen, D. J.; Bidlack, J. M. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Bioorg. Med. Chem. 2008, 16, 5653-5664.
34. Kosson, P.; Bonney, I.; Carr, D. B.; Lipkowski, A. W. Endomorphins interact with tachykinin receptors. Peptides 2005, 26, 1667-1669.
35. Pello, O. M.; Martínez-Muñoz, L.; Parrillas, V.; Serrano, A.; Rodrígues-Frude, J. M.; Toro, M. J.; Lucas, P.; Monterrubio, M.; Martínez-A, C.; Mellado, M. Ligand stabilization of CXCR4/δ-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur. J. Immunol. 2008, 38, 537-549.
36. Koda, Y.; Del Borgo, M.; Wessling, S. T.; Lazarus, L. H.; Okada, Y.; Toth, I.; Blanchfield, J. T. Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg. Med. Chem. 2008, 16, 6286-6296.
37. Lesscher, H. M.; Bailey, A.; Burbach, J. P.; Van Ree, J. M.; Kitchen, I.; Gerrits, M. A. Receptor-selective changes in mu-, delta-, and kappa-opioid receptors after chronic naltrexone treatment in mice. Eur. J. Neurosci 2003, 17, 1006-1012.
38. Cahill, C. M.; Holdridge, S. V.; Morinville, A. Trafficking of δ-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol. Sci. 2007, 28, 23-31.
39. Archer-Lahlou, E.; Audet, N.; Amraei, M. G.; Huard, K.; Paquin-Gobeil, M.; Pineyro, G. Src promotes delta opioid receptor (DOR) desensitization by interfering with receptor recycling. J. Cell. Mol. Med. 2008, . in press, doi:, 10.1111/j.1582-4934.2008.00308.x.
40. Lazarus, L. H.; Salvadori, S.; Santagada, V.; Tomatis, R.; Wilson, W. E. Function of negative charge in the "address domain" of deltorphins. J. Med. Chem. 1991, 34, 1350-1355.
41. Lazarus, L. H.; Salvadori, S.; Attila, M.; Grieco, P.; Bundy, D. M.; Wilson, W. E.; Tomatis, R. Interaction of deltorphin with opioid receptors: Molecular determinants for affinity and selectivity. Peptides 1993, 14, 21-28.
42. Lazarus, L. H.; Wilson, W. E.; de Castglione, R.; Guglietta, A. Dermorphin gene sequence peptide with high affinity and selectivity for δ-opioid receptors. J. Biol. Chem. 1989, 264, 3047-3050.
43. i) and the concentration of inhibitor which cause 50% (IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
44. Sasaki, Y.; Sasaki, A.; Niizuma, H.; Goto, H.; Ambo, A. Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high μ-opioid receptor affinity and selectivity. Bioorg. Med. Chem. 2003, 11, 675-678.
45. Arunlakshana, Q.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
46. Laursen, S. E.; Belknap, J. K. Intracerebroventricular injections in mice. Some methodological refinements. J. Pharmacol. Methods 1986, 16, 355-357.
47. 1]endomorphin-1. Pharmacol., Biochem. Behav. 2006, 84, 252-258.
48. 1]-Endomorphins are μ-opioid receptor antagonists lacking inverse agonist properties. J Pharmacol Exp Ther. 2007, 323, 374-380.
49. Kosterlitz, H. W.; Watt, A. J. Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone). Br. J. Pharmacol. 1968, 33, 266-276.